Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) announced Monday that an article showcasing the benefits of its anti-inflammatory drug candidate has been published in a medical journal.
The piece, which appeared in the publication “Antioxidant and Redox Signaling,” reported on a series of studies of ATB-352, the company’s derivative of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen.
The studies show that ATB-352 induces greater pain relief than ketoprofen in a well-characterized animal model of surgical pain.
In addition to blocking the production of pain-promoting substances called “prostaglandins”, the company said, ATB-352 further reduced pain by elevating levels of naturally-occurring endocannabinoids in comparison to the levels of endocannabinoids observed in mice treated with ketoprofen.
Like ketoprofen, ATB-352 treats pain by releasing hydrogen sulfide, but Antibe’s alternative is being developed to also avoid some of its side effects, namely damage to the gastrointestinal tract.
The studies were led by Antibe Chief Science Officer John Wallace and featured researchers from the University of Calgary in Canada; the University of Sao Paulo and the University of Campinas in Brazil; and Umea University in Sweden.
Toronto-based Antibe is also working to develop and commercialize its lead drug, ATB-346, which targets acute and chronic pain associated with osteoarthritis.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel